Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced ...

Two new studies from Johns Hopkins University are providing scientists with an unprecedented view of how human cells repair ...

AI, combined with genomics, biotechnology and synthetic biology, is beginning not merely to read biology, but to understand, ...

Explore how whole exome sequencing works, how capture design determines what is actually covered, and when whole genome sequencing is the better choice.

An overview of where next-generation sequencing is used, from whole-genome variant discovery to clinical liquid biopsy and single-cell transcriptomics.

CRISPR-Cas provides RNA-mediated adaptive immunity, but how its first RNA-guided effector arose is unclear. In this study, we report the discovery of Viral Interference Programmable Repeat (VIPR) ...

New proprietary AI product turns a brand's design system into machine-readable code, so agents can apply brand correctly ...

AlphaGenome Atlas is available today through an intuitive website portal, our AlphaGenome API, and as a skill in Google ...

Scientists have long believed that large stretches of our genetic material, known as long noncoding RNAs (lncRNAs), help ...

Google DeepMind’s AlphaGenome Atlas maps 9 billion DNA variants, turning massive AI predictions into a resource for ...

What is it?: AlphaGenome Atlas is a 1-petabyte AI-generated database predicting the effects of every possible single-letter DNA change in humans. Why it matters: It helps researchers prioritise ...